Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of lenvatinib in advanced grade 1/2 neuroendocrine neoplasms
2015-001467-39Phase 2Active
- Sponsor
- Spanish Group of Neuroendocrine Tumors
- Start
- Jul 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of lenvatinib in apudoma (NET) and gastrointestinal carcinoid tumor (2 cohorts), sponsored by Spanish Group of Neuroendocrine Tumors. Primary endpoint: Overall response rate by RECIST v1.1. Started Jul 2015; status: active.
02
Drugs
lenvatinib
03
Conditions
apudoma (NET)gastrointestinal carcinoid tumor
Beyond the preview
Go deeper on 2015-001467-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001467-39.